1. Home
  2. NCNA vs RVPH Comparison

NCNA vs RVPH Comparison

Compare NCNA & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$1.56

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.81

Market Cap

10.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
RVPH
Founded
1997
2006
Country
United Kingdom
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
10.0M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
NCNA
RVPH
Price
$1.56
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$66.67
AVG Volume (30 Days)
43.2K
1.5M
Earning Date
03-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.17
52 Week High
$10.00
$3.11

Technical Indicators

Market Signals
Indicator
NCNA
RVPH
Relative Strength Index (RSI) 35.13 45.62
Support Level $0.03 $0.32
Resistance Level $2.27 $0.86
Average True Range (ATR) 0.13 0.19
MACD 0.01 -0.12
Stochastic Oscillator 31.57 10.36

Price Performance

Historical Comparison
NCNA
RVPH

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: